I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

This will be Sanofi's largest single investment in China since entering the country in 1982. Sanofi has not been alone ...

Winners of 2024 DEI Employer® Awards. 2024 DEI Employer® Awards. 2024 DEI Employer® Awards & Top 100 DEI Employer® SHANGHAI, CHINA, January 6, 2025 /EI ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

Investors often hold blue-chip stocks at the core of their portfolios. That makes sense. After all, blue-chip companies are ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

China's economy demonstrated remarkable resilience and adaptability in 2024 amid complex domestic and global landscapes. The ...

Sanofi has said it plans to start discussions ... while remibrutinib is in phase 3 for relapsing MS. China's InnoCare was partnering with Biogen on the development of orelabrutinib, which is ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...